Member Info for inanaco

Put a number on how much has been spent by research institutions worldwide on Cancer in the last 50 years

https://www.bbc.co.uk/news/health-45497304

our market is not getting smaller ................ LOL

and the only trial data we have shows it works ...

Val would love that data

The Regulator's .. who have to sign off the trials .. have never heard of a

Cytotoxic CD4 killer T cell ... with a controlled TH1 phenotype

Modi1 ......... is the first time ever that a vaccine has been developed with this outcome ....

I can guarantee that if you walked into 99% of Dr Surgeries and asked them ... they would not know it existed

only Dr treating maybe Malaria may of heard about it.

so basically ... for a few million. spent now we ignore the Billion in sales to come ?

The Patent is Time Limited !!

tick tock

Not really sure why you keep post REC very poorly written posts ... which repeat over and over the same Miss Information that they claim to understand the market .. when actually it's the market that does not understand Scancell

Announce we have a "target" ...... it will eventually become a cash register

DISEASE OVERVIEW
Triple-negative breast cancer is characterized by the absence of estrogen and progesterone receptors, and does not involve overexpression of human epidermal growth factor 2 (HER2). It is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. Overall, breast cancer is the second most common cancer and the second leading cause of cancer-related deaths in women worldwide. In the US, breast cancer is the third leading cause of cancer-related deaths, regardless of gender, behind lung cancer and colorectal cancer.

MARKET SNAPSHOT
Sales will exceed $1bn by 2024, driven by the introduction and uptake of next-generation targeted therapies

I cannot see the point of posting such an unbalanced view ....

you have missed out Amplivant ... and all the discussions around it.

You have missed out the new Ichor Gun and all the discussions around that ...

its because the market is superficial in that it only reads the headline is the reason why the SP is so low.

whats so strange that all the serious investors keep buying . indeed treat it as an opportunity rather than problem

That is what you don't do !! and it come's across in the posts

you seem to forget the science development of SCIB1 is over ... its regulatory now, so you cannot just concentrate on one particular area as its impossible to speed up process ... that applies to Modi1 as well ... min 12 month manufacturing time ...with all the tox tests etc.

so the issue is you making quite bold statements without the full understanding of the reasons why and how the development process functions ...

how can you for instance speed up a mouse experiment ? do you think the final output results of the developed vaccine comes from 1 cohort of mice ?

The fact is the market of simplify's and expects results as if this frontier research had been done before ..
It has NOT ... so even the manufacture of the first Modii1 Hydrophobic conjugates had

The PolyPeptide Group is a privately-held organisation which is estimated to manufacture over one third of all approved peptide drug substances and has an exclusive focus on pharmaceutical peptide manufacture.

with all the experience they had ... struggled to manufacture

As expected, and in line with the Company's commercialisation plans, an option fee will be payable (within 30 days of exercise) to Ichor,

Paid

if you can strip out the one off costs then you could estimate current cash burn rates,

this guess work is not helping ...

what a dumb statement .......... hope you are proud of yourself ..

I would not do any calculations as we could be plus or minus a million ... because of 1 off capital expenditure, we are not sure if its paid upfront or arrears ie .. Modi1 manufacture

i

its not Rucks suggestion ..

its in RNS

These two appointments are significant for Scancell as we expand our R&D and manufacturing capabilities in order to further advance our ImmunoBody® and Moditope® pipeline products through clinical development."

yes mate that looks about right, but we have to add back in Tax Credits .. closer to year end

so i see no reason why we would need a capital raise this year ..

so i expect at least some indication from the Scib1 trial before we need funding

and i hope that the TCR collaboration will announce before then .. this delay in SCIB1 may actually be of use allowing that deal to formalise

Found it

Richard said it ............ https://youtu.be/-u-UBZTS1_w

Inclusive costs of about £5m

well we have £8.7 m in the bank

with all regulatory cost and manufacturing costs already covered, and we are only running the phase 2 part

Its interesting who mentioned SCIB2 would cost CRUK £5m of funding approx as its a Phase 1/2 including cost of manufacture ?

yes agree ....

However Ivy is the one for """ caused some panic spelling""" googlegook etc

what company issues an rns every time they pay a bill ? and what it was for, as that is what you are asking

the issue is C7 every cost is a one off depending on which program ...

the only static number is wages/heating lighting etc

"""" BTW I was thinking about project blueprint... I think we were wrong about a TCR element to it... it was going to be BioNTech/Genentechs mRNA and moditope -modi3 vaccine.... I think it would have been much like this : """"

Modi 3 is not a personal vaccine as the epitopes are found on so many cancers ...

the cancers under review in CRUK Grand Ch. are all compatible with the Modi1/2 epitopes ranges of Vim and Eno

the principle was about building a Template ... of the best way to treat and that must including staging ... ie you don't give moditope to a resected patient ...

Agree .. Crumbs

But the penny has only just dropped ...

once you add the words TCR ... it gives the game away